Biodexa Pharmaceuticals (BDRX) Competitors

$3.40 -0.31 (-8.36%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$3.30 -0.10 (-2.94%)

As of 04:03 AM Eastern

BDRX vs. VTGN, AEON, TXMD, AKAN, and VYNE

Should you buy Biodexa Pharmaceuticals stock or one of its competitors? MarketBeat compares Biodexa Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biodexa Pharmaceuticals include VistaGen Therapeutics (VTGN), AEON Biopharma (AEON), TherapeuticsMD (TXMD), Akanda (AKAN), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical products" industry.

How does Biodexa Pharmaceuticals compare to VistaGen Therapeutics?

VistaGen Therapeutics (NASDAQ:VTGN) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Biodexa Pharmaceuticals' return on equity of 0.00% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	N/A	-109.72%	-89.62%
Biodexa Pharmaceuticals	N/A	N/A	N/A

VistaGen Therapeutics presently has a consensus price target of $0.95, indicating a potential upside of 46.02%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe VistaGen Therapeutics is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biodexa Pharmaceuticals has lower revenue, but higher earnings than VistaGen Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$490K	52.61	-$51.42M	-$1.89	N/A
Biodexa Pharmaceuticals	$470K	14.47	-$8.42M	N/A	N/A

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

VistaGen Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

In the previous week, VistaGen Therapeutics and VistaGen Therapeutics both had 3 articles in the media. Biodexa Pharmaceuticals' average media sentiment score of 1.44 beat VistaGen Therapeutics' score of 0.87 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodexa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

VistaGen Therapeutics beats Biodexa Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to AEON Biopharma?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 9.4% of AEON Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 3 mentions for Biodexa Pharmaceuticals and 2 mentions for AEON Biopharma. Biodexa Pharmaceuticals' average media sentiment score of 1.44 beat AEON Biopharma's score of 0.00 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodexa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AEON Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
AEON Biopharma	N/A	N/A	-994.63%

Biodexa Pharmaceuticals has higher revenue and earnings than AEON Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	14.47	-$8.42M	N/A	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$2.43	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Biodexa Pharmaceuticals has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Summary

Biodexa Pharmaceuticals beats AEON Biopharma on 6 of the 11 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to TherapeuticsMD?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

TherapeuticsMD has higher revenue and earnings than Biodexa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	14.47	-$8.42M	N/A	N/A
TherapeuticsMD	$3.02M	7.62	-$570K	-$0.01	N/A

TherapeuticsMD has a net margin of 5.34% compared to Biodexa Pharmaceuticals' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Biodexa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
TherapeuticsMD	5.34%	0.32%	0.23%

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Biodexa Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, TherapeuticsMD had 2 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 5 mentions for TherapeuticsMD and 3 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 1.44 beat TherapeuticsMD's score of 1.17 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodexa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TherapeuticsMD	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TherapeuticsMD beats Biodexa Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Akanda?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

Biodexa Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Akanda has a beta of 14.49, suggesting that its share price is 1,349% more volatile than the broader market.

In the previous week, Akanda had 3 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 6 mentions for Akanda and 3 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 1.44 beat Akanda's score of 0.89 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodexa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akanda	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Comparatively, 20.4% of Akanda shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Akanda	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Akanda has higher revenue and earnings than Biodexa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	14.47	-$8.42M	N/A	N/A
Akanda	$840K	15.71	-$4.10M	N/A	N/A

Summary

Akanda beats Biodexa Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

VYNE Therapeutics has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

Biodexa Pharmaceuticals has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,646.14%. Biodexa Pharmaceuticals' return on equity of 0.00% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,646.14%	-74.86%	-63.87%
Biodexa Pharmaceuticals	N/A	N/A	N/A

Biodexa Pharmaceuticals has lower revenue, but higher earnings than VYNE Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	39.19	-$26.48M	-$0.78	N/A
Biodexa Pharmaceuticals	$470K	14.47	-$8.42M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Biodexa Pharmaceuticals had 2 more articles in the media than VYNE Therapeutics. MarketBeat recorded 3 mentions for Biodexa Pharmaceuticals and 1 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 1.89 beat Biodexa Pharmaceuticals' score of 1.44 indicating that VYNE Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
VYNE Therapeutics	Very Positive
Biodexa Pharmaceuticals	Positive

Summary

VYNE Therapeutics beats Biodexa Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Biodexa Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDRX vs. The Competition

Export

Metric	Biodexa Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.42M	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	N/A	18.47	20.66	25.63
Price / Sales	14.47	294.84	545.73	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	0.03	6.93	9.94	6.97
Net Income	-$8.42M	$24.11M	$3.55B	$333.62M
7 Day Performance	-20.00%	5.89%	1.70%	1.09%
1 Month Performance	-0.87%	-0.91%	0.49%	3.08%
1 Year Performance	-94.77%	74.58%	39.38%	35.68%

Biodexa Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDRX Biodexa Pharmaceuticals	1.1594 of 5 stars	$3.40 -8.4%	N/A	-94.8%	$7.42M	$470K	N/A	20	News Coverage Positive News Short Interest Decrease Gap Down
VTGN VistaGen Therapeutics	2.549 of 5 stars	$0.60 -3.6%	$0.95 +58.3%	-71.2%	$24.66M	$490K	N/A	40
AEON AEON Biopharma	0.8368 of 5 stars	$0.94 -1.1%	N/A	+60.9%	$24.04M	N/A	5.22	5	News Coverage Upcoming Earnings
TXMD TherapeuticsMD	0.8584 of 5 stars	$2.07 +2.5%	N/A	+36.3%	$23.38M	$3.02M	N/A	420	News Coverage Earnings Report Upcoming Earnings High Trading Volume
AKAN Akanda	0.8035 of 5 stars	$30.00 -27.0%	N/A	-69.5%	$21.95M	$840K	N/A	110	Short Interest Increase Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDRX) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. VTGN, AEON, TXMD, AKAN, and VYNE

How does Biodexa Pharmaceuticals compare to VistaGen Therapeutics?

Summary

How does Biodexa Pharmaceuticals compare to AEON Biopharma?

Summary

How does Biodexa Pharmaceuticals compare to TherapeuticsMD?

Summary

How does Biodexa Pharmaceuticals compare to Akanda?

Summary

How does Biodexa Pharmaceuticals compare to VYNE Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. VTGN, AEON, TXMD, AKAN, and VYNE

How does Biodexa Pharmaceuticals compare to VistaGen Therapeutics?

Is VTGN or BDRX more profitable?

Do analysts prefer VTGN or BDRX?

Which has preferable earnings & valuation, VTGN or BDRX?

Do insiders & institutionals hold more shares of VTGN or BDRX?

Which has more risk and volatility, VTGN or BDRX?

Does the media refer more to VTGN or BDRX?

Summary

How does Biodexa Pharmaceuticals compare to AEON Biopharma?

Do insiders and institutionals believe in BDRX or AEON?

Does the media favor BDRX or AEON?

Is BDRX or AEON more profitable?

Which has stronger valuation and earnings, BDRX or AEON?

Do analysts prefer BDRX or AEON?

Which has more volatility & risk, BDRX or AEON?

Summary

How does Biodexa Pharmaceuticals compare to TherapeuticsMD?

Which has higher valuation & earnings, BDRX or TXMD?

Is BDRX or TXMD more profitable?

Do institutionals and insiders believe in BDRX or TXMD?

Which has more risk & volatility, BDRX or TXMD?

Do analysts prefer BDRX or TXMD?

Does the media favor BDRX or TXMD?

Summary

How does Biodexa Pharmaceuticals compare to Akanda?

Which has more risk and volatility, BDRX or AKAN?

Does the media prefer BDRX or AKAN?

Do insiders and institutionals have more ownership in BDRX or AKAN?

Is BDRX or AKAN more profitable?

Do analysts recommend BDRX or AKAN?

Which has higher earnings and valuation, BDRX or AKAN?

Summary

How does Biodexa Pharmaceuticals compare to VYNE Therapeutics?

Which has more volatility & risk, VYNE or BDRX?

Is VYNE or BDRX more profitable?

Which has higher earnings & valuation, VYNE or BDRX?

Do analysts rate VYNE or BDRX?

Do institutionals and insiders hold more shares of VYNE or BDRX?

Does the media favor VYNE or BDRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools